Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors
AssigneeG1 Therapeutics, Inc.
InventorsJay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
Life of this patent
Estimating the term…
Abstract
This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with a Bruton's tyrosine kinase (BTK) inhibitor.
Claims6
A method for the treatment of acute myeloid leukemia (AML) in a human in need thereof comprising administering an effective amount of Bruton's tyrosine kinase (BTK) inhibitor selected from ibrutinib and acalabrutinib in combination with a CDK 4/6 inhibitor compound of the structure
- or a pharmaceutically acceptable salt thereof.
A method for the treatment of acute lymphoblastic leukemia (ALL) in a human in need thereof comprising administering an effective amount of Bruton's tyrosine kinase (BTK) inhibitor selected from ibrutinib and acalabrutinib in combination with a CDK 4/6 inhibitor compound of the structure
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.